Hospital

Joseph Saseen, PharmD, addresses statin intolerance and misinformation and provides a look at aggressive new LDL targets and emerging therapies not yet captured in the 2026 guidelines.

AHA Epidemiology Sessions 2026 show that chronic kidney disease (CKD) proteinuria drops of 30% or more cut heart failure, major adverse cardiovascular events, and death, a key prevention signal.

Jonathan Leung, PharmD, RPh, BCPS, discusses the ongoing underutilization of clozapine despite its efficacy, highlighting clinician concerns, lingering perceptions, and the key role pharmacists play in improving its use through education and monitoring.

Fluvoxamine significantly reduced fatigue in adults with long COVID, with a 99% probability of outperforming placebo.

At APhA 2026, Callan Bleick, PharmD, MSc, laid out a stark picture of antimicrobial resistance, vaccine-preventable disease resurgence, and updated treatment guidelines.

Selinexor plus ruxolitinib significantly improved spleen volume reduction in JAK inhibitor–naive myelofibrosis, supporting its potential as a novel frontline combination strategy.

Martinez Sanchez describes early signs of Parkinson disease, how treatment adapts, and how ambulatory pharmacists fine-tune treatment, adherence, and hope amid new therapies.

Pharmacists' role in lipid management takes center stage with the 2026 dyslipidemia guideline update.

Eduardo Martinez Sanchez, PharmD, CPh, BCPS, BCACP, discusses key counseling points, the importance of individualizing disease management, and promising therapies to keep an eye on.

A phase 3 trial found that the oral PCSK9 inhibitor enlicitide significantly outperformed existing oral therapies in lowering LDL cholesterol.

New research identifies caspase-8 loss as a key driver of inflammatory reprogramming and tumor recurrence in small cell lung cancer.

The trial's success offers the first robust evidence for targeted pharmacologic intervention in adolescent oHCM.

For decades, the medical community has operated under a reactive model for the most potent cholesterol-lowering drugs, largely reserving them for secondary prevention.

The findings emphasize that when it comes to the complex machinery of human blood pressure, more drug is not always better.

With updated recommendations for adults aged 50 and older, pharmacy teams are uniquely positioned to bridge gaps in care through community engagement and proactive clinical assessments.

Gene and cell therapies are reshaping clinical workflows—and pharmacists are becoming essential guides in that shift.

Historically, dulaglutide was a preferred choice because it was proven to reduce major adverse cardiovascular events in the REWIND trial.

The RECOVER-AUTONOMIC trial underscores the necessity of better clinical end points to assess interventions in the long COVID population.

CHAMPION-AF may potentially lead to a shared decision-making process between a lifetime of medication and a one-time catheter-based procedure.

Formal preceptor leadership pathways can reduce RPD burden and improve resident support across programs.

In a session at the American Pharmacists Association Annual Meeting, Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, provided practical insights for pharmacists to optimize the care of patients with cardio-kidney-metabolic conditions.

CDC flags a late respiratory syncytial virus (RSV) rise, while the NFID urges spring vigilance, vaccines, and monoclonals to protect infants and older adults from this virus.

Joseph Saseen, PharmD, explains the 2026 dyslipidemia guidelines' push for universal lipoprotein A screening, clarifies when apolipoprotein B testing adds value, and outlines how new FDA-approved therapies fit into the updated lipid-lowering treatment algorithm.

The safety and effectiveness of marne-cel were established in an open-label, single-arm, multicenter phase 1/2 clinical trial.